Sector consensus Scholar Rock Holding Corporation

Stocks

Market Closed - Nasdaq 00:00:00 05/09/2026 +04			5-day change	1st Jan Change
55.33 ^USD	-1.09%		-4.27%	+25.61%

09-02	Scholar Rock Receives FDA Fast Track Designation For Apitegromab Facioscapulohumeral Muscular Dystrophy Program As Participant Dosing Commences In Phase 2 FORGE Trial	CI
09-02	Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Objective/dr gap	Nbr of analysts
SCHOLAR ROCK HOLDING CORPORATION	60.75	+9.8%	16
WUXI APPTEC CO., LTD.	186.27	+21.09%	18
ARGENX SE	1,162.61	+11.95%	15
INSMED INCORPORATED	200.18	+58.51%	22
BIONTECH SE	103.52	+15.94%	20
WUXI BIOLOGICS (CAYMAN) INC.	49.16	+16.61%	24
GENMAB A/S	2,427.12	+12.11%	15
PHARMAESSENTIA CORPORATION	1,397.26	+6.66%	8
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	618.43	+26.36%	18
EXELIXIS, INC.	53.69	-9.02%	16
SUMMIT THERAPEUTICS INC.	21.01	+61.52%	13
MADRIGAL PHARMACEUTICALS, INC.	678.06	+25.32%	16
ARROWHEAD PHARMACEUTICALS, INC.	110.18	+27.61%	11
AKESO, INC.	134.69	+55.44%	21
CYTOKINETICS, INCORPORATED	109.9	+51.13%	20
VAXCYTE, INC.	109	+78.22%	9
REMEGEN CO., LTD.	100.21	+45.99%	16
IMMUNITYBIO, INC.	12.75	+57.8%	4
SPYRE THERAPEUTICS, INC.	119.69	+34.52%	13
BELITE BIO, INC	223.89	+15.64%	9
Average	393.92	+31.16%	15
Weighted average by Cap.	510.35	+25.85%	16